Previous 10 | Next 10 |
Findings from a new study, published Ultrasound in Obstetrics and Gynecology , showed a high rate of accuracy for Myrida Genetics' ( MYGN +4.7% ) noninvasive Prequel Prenatal Screen test in addition to a low test-failure rate of 1/1,000. More news on: Myriad Genetics, Inc., Healt...
SALT LAKE CITY, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new study of the Prequel™ Prenatal Screen was publish...
by Daniel Shvartsman Listen to or subscribe to The Investing Edge on these podcast platforms: Apple Podcasts Spotify Google Play Stitcher Seeking Alpha On this week's The Razor's Edge, we discussed Akram's Razor's recent short case on Invitae (NVTA). If...
SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data on the Vectra test at the 2019 ACR/ARP Annual Meeting being held Nov. 8-13, 2019 in Atl...
SAN FRANCISCO , CA / ACCESSWIRE / November 7, 2019 / Hagens Berman urges Myriad Genetics, Inc. (NASDAQ:MYGN) investors who have suffered losses in excess of $50,000 to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. A secu...
SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens Nashville Investment Conference at 12:15 p.m. EST on November 1...
Major benchmarks saw a lot of ups and downs on Tuesday as investors tried to come to a consensus about the likely future direction of the global economy. Signs of progress in trade talks between the U.S. and China led to early gains, but some broader concerns about various economic issues weighe...
Shares of Myriad Genetics (NASDAQ: MYGN) fell over 42% today after the company reported fiscal first-quarter 2020 operating results. The latest numbers make it clear that the genetic testing pioneer continues to struggle, which is all the more surprising considering peers and competitors a...
Myriad Genetics (NASDAQ: MYGN ) -38% on Q3 results . More news on: Myriad Genetics, Inc., Shake Shack Inc., Reebonz Holding Limited, Stocks on the move, Read more ...
Myriad Genetics (NASDAQ: MYGN ) fiscal Q1 results : More news on: Myriad Genetics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply d...
Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal ( 22% ), Pharmacogenomics ( 21% ), and Hereditary Cancer ( 16% ). First quarter average revenue per test improved by 2% over the prior year...